Long-standing COVID-19 infection outcomes like cognitive & functional, and acute neurological complexities are less discussed, presented, and documented substantially.
It includes breathing & gastrointestinal difficulties, sleep disturbances, frequent headaches, anxiety episodes, depressed feelings, attention impairment & loss of memory.
In inappropriately handled long-lasting hospitalized patients warning consequences of chronic stage causes mental challenges & “brain fog”.
Long COVID care demands the development of patient-centered preventive measures, rehabilitation techniques & clinical management procedures. Simultaneously detailed analysis and understanding of the prevalence, risk factors, and pathophysiology of brain fog is crucial.
In post-acute sequelae, COVID-19 patients, structural & functional abnormalities of frontal, temporal, and limbic areas develop.
Olfactory network structural changes including prefrontal structures, corpus callosum and insula involvement, temporal lobe, basal ganglia, brainstem, and cerebellum are the most reported.
The cognitive disturbance duration depends on the severity of cognitive damage.
Brain fog is a descriptive terminology & is explained by the patients as a diverse bunch of intellectual function-related complications comprising trouble in thinking, remembering, and reasoning that interferes with daily functioning and instigates neuropsychological dysfunctions.
As per the World Health Organization (WHO), brain fog is defined as an informal term for a common complaint of intellectual functions among patients with post-acute COVID-19. Impairment of cognitive function, confusion, short-term memory loss, dizziness, and inability to concentrate come under brain fog.
It is a common characteristic in healing or recovering patients affecting their higher cognitive or “executive” function.
Brain fog requires serious attention from medical practitioners in employing its instructive & protective procedures.
Virus-induced long-standing & neurodegeneration cognitive impairment denotes the hippocampal distribution of microglial activation, systemic inflammation & sepsis.
Severe acute intensive care patients of COVID-19 develop hypoxia, vascular nerve cell injury & endothelial dysfunction associated with microvascular damage. Concomitantly immunological dysregulation, chronic inflammation & peripheral organ dysfunction occur. Cerebral white matter becomes vulnerable to ischaemic injury, cerebral hypoperfusion, amyloid-beta rapid accumulation, and TAR DNA binding protein-43 pathology.
There are also chances of systemic inflammatory injury & abnormalities, blood-brain barrier permeability increase & disturbance in tight junction proteins associated with brain parenchyma.
Cognition controlling the hippocampus, temporal lobe, and thalamus gets affected by thrombotic and inflammatory cascade leading to capillary occlusion, and ischemia.
Suitable intervention strategies, scientific community-based future studies & trials can reduce long-lasting COVID-19-related cognitive diminishing symptoms & their effects.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?
2.
DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance
3.
For patients with prostate cancer, long-term follow-up helps identify treatment side effects.
4.
Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?
5.
Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects
1.
Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics
2.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
3.
Precision Cancer Risk Mitigation Strategies
4.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
5.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
2.
Efficient Management of First line ALK-rearranged NSCLC - Part II
3.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
Innovations in Hematology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation